Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Abdominal pain-related functional gastrointestinal disorders (FGIDs) are among the most common medical problems in paediatric medicine. Frequently, physicians prescribe antidepressants as a second-line treatment for children and adolescents with FGIDs. To date, the evidence on the benefits and harms of antidepressants for the treatment of abdominal pain-related FGIDs has not been assessed systematically. OBJECTIVES: The primary objectives were to conduct a systematic review to evaluate the efficacy and safety of antidepressants for the treatment of abdominal pain-related FGIDs in children and adolescents. SEARCH STRATEGY: We searched The Cochrane Library, PubMed, EMBASE, IPA, CINAHL, PsycINFO, ISI Web of Science, Biosis Previews and the International Clinical Trials Registry Platform of the World Health Organization with appropriate filters (from inception to January 31, 2011). SELECTION CRITERIA: For efficacy we included double-blind, randomised controlled trials (RCTs) of antidepressants for treatment of abdominal pain-related FGIDs in children and adolescents 18 years or younger. Open-label and uncontrolled experimental studies, as well as observational studies were eligible for the assessment of harms. The minimum study duration was 4 weeks. The minimum study size was 30 participants. DATA COLLECTION AND ANALYSIS: Two authors independently assessed all abstracts and full text articles, and rated the risk of bias for included studies. Data were extracted independently by one author and checked for accuracy by another author. Data were analysed using RevMan 5. MAIN RESULTS: Two RCTs (123 participants), both using amitriptyline, met the pre-specified inclusion criteria. These studies provided mixed findings on the efficacy of amitriptyline for the treatment of abdominal pain-related FGIDs. The larger, publicly-funded study reported no statistically significant difference in efficacy between amitriptyline and placebo in 90 children and adolescents with FGIDs after 4 weeks of treatment. On intention-to-treat (ITT)- analysis, 59% of the children reported feeling better in the amitriptyline group compared with 53% in the placebo group (RR 1.12; 95% CI: 0.77 to 1.63; P = 0.54). The risk of bias for this study was rated as low.The second RCT enrolled 33 adolescents with irritable bowel syndrome. Patients receiving amitriptyline experienced greater improvements in the primary outcome, overall quality of life, at weeks 6, 10, and 13 compared with those on placebo (P= 0.019, 0.004, and 0.013, respectively). No effect estimates were calculated for the quality of life outcome because mean quality of life scores and standard deviations were not reported. For most secondary outcomes no statistically significant differences between amitriptyline and placebo could be detected. The risk of bias for this study was rated as unclear for most items. However, it was rated as high for other bias due to multiple testing. The results of this study should be interpreted with caution due to the small number of patients and multiple testing.The larger study reported mild adverse events including fatigue, rash and headache and dizziness. On ITT analysis, 4% of the amitriptyline group experienced at least one adverse event compared to 2% of the placebo group. There was no statistically significant difference in the proportion of patients who experienced at least one adverse event (RR 1.91; 95% CI 0.18 to 20.35; P = 0.59). The smaller study reported no adverse events. The methods of adverse effects assessment was poorly reported in both studies and no clear conclusions on the risks of harms of amitriptyline can be drawn. AUTHORS' CONCLUSIONS: Clinicians must be aware that for the majority of antidepressant medications no evidence exists that supports their use for the treatment of abdominal pain-related FGIDs in children and adolescents. The existing randomised controlled evidence is limited to studies on amitriptyline and revealed no statistically significant differences between amitriptyline and placebo for most efficacy outcomes. Amitriptyline does not appear to provide any benefit for the treatment of FGIDs in children and adolescents. Studies in children with depressive disorders have shown that antidepressants can lead to substantial, sometimes life-threatening adverse effects. Until better evidence evolves, clinicians should weigh the potential benefits of antidepressant treatment against known risks of antidepressants in paediatric patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Quartero, A. O., Meiniche-Schmidt, V., Muris, J., Rubin, G., & de Wit, N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003460.pub2 · Cited by 190
Cited by
Managing Chronic Pain in Children and Adolescents: A Clinical Review
Landry, B. W., Fischer, P. R., Driscoll, S. W., Koch, K. M., Harbeck‐Weber, C., Mack, K. J., Wilder, R. T., Bauer, B. A., & Brandenburg, J. E. (2015) · PM&R · doi:10.1016/j.pmrj.2015.09.006 · Cited by 128
“5 mg/kg/day, with a target dose typically 1-2 mg/kg/day) seem to help some patients [34] but are not uniformly helpful [35].”
Pain management in patients with inflammatory bowel disease: insights for the clinician
Srinath, A. I., Walter, C., Newara, M. C., & Szigethy, E. M. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12446158 · Cited by 111
“In their review, Kaminski and colleagues [Kaminski et al. 2011] examined two pediatric studies that evaluated the effects of amitriptyline on pediatric patients with functional GI disorders [Bahar et al.”
BackgroundPediatric inflammatory bowel disease and depression: treatment implications
Keethy, D., Mrakotsky, C., & Szigethy, E. (2014) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000129 · Cited by 40
“In particular, noradrenergic agents such as tricyclic antidepressants have been found to be effective for pain and other residual symptoms of IBD in adults, but findings are more mixed for children [76,77].”
BackgroundAbbott, R. A., Martin, A. E., Newlove‐Delgado, T. V., Bethel, A., Whear, R. S., Thompson Coon, J., & Logan, S. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001922 · Cited by 36
Functional abdominal pain: What clinicians need to know
Andrews, E. T., Beattie, R. M., & Tighe, M. P. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-318825 · Cited by 25
Metadata
- Authors
- Kaminski, A., Kamper, A., Thaler, K., Chapman, A., & Gartlehner, G.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2011-07-06
- Issue
- 7
- Pages
- CD008013-CD008013
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1573836274
- Cited by
- 63
- References
- 5
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. https://app.cochat.ai/papers/10.1002/14651858.cd008013.pub2
- The paper
- Kaminski, A., Kamper, A., Thaler, K., Chapman, A., & Gartlehner, G. (2011). Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008013.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.